The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine

Yu-cheng Wang1,2, Marlene B Zuraek1,2, Yasuhiro Kosaka3, Yasuharu Ota3, Michael S German3,4, Evan S Deneris5, Emily K Bergsland1,4, David B Donner1,2, Robert S Warren1,2 and Eric K Nakakura1,2

1UCSF Helen Diller Family Comprehensive Cancer Center, 2Department of Surgery, 3Hormone Research Institute, Diabetes Center and 4Department of Medicine, University of California, 1600 Divisadero Street, A-724, San Francisco, California 94143-1932, USA 5Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

Abstract

Neuroendocrine (NE) or carcinoid tumors of the small intestine (SI) frequently metastasize and produce the hormone serotonin, causing significant morbidity and mortality. A member of the ETS oncogene family of transcription factors, Fev, acts with the homeodomain transcription factor Nkx2.2 in the development of serotonin neurons in mice. In this study, we investigated the role of Fev in normal and neoplastic SI. In NE tumors (NETs) of the SI, serotonin stimulates tumor growth and causes debilitating symptoms, such as diarrhea, flushing, wheezing, and right-sided valvular heart disease (i.e. carcinoid syndrome). Compared with those in the matched normal human SI, FEV expression levels were significantly elevated in primary NETs (20-fold, \( P < 0.0001 \)), lymph node metastases (35-fold, \( P = 0.004 \)), and NET liver metastases (22-fold, \( P < 0.0001 \) ) resected from patients with serotonin excess. Fev is expressed in the wild type but not in Nkx2.2 (−/−) mouse SI, in which cells producing serotonin are absent. Using recombination-based cell lineage tracing, we found that FEV-positive cells give rise to serotonin-producing cells in the SI. In Fev (−/−) mouse SI, we observed no difference in the number of cells producing serotonin or other hormones. We conclude that FEV expression identifies serotonin-producing cells in normal and neoplastic SI and is a novel target for diagnosis of patients with NETs of the SI.

Endocrine-Related Cancer (2010) 17 283–291

Introduction

The incidence of neuroendocrine (NE) – or carcinoid – tumors has increased over the past 30 years to 2.5–5 individuals/100 000 per year in the US (Modlin et al. 2003, 2008). The predominant sites of origin for NE tumors (NETs) are the gastrointestinal (GI) and bronchopulmonary systems (Hauso et al. 2008), and within the GI tract, the small intestine (SI) is the most common site (Modlin et al. 2007). For most patients with GI-NETs, surgery, the only potentially curative treatment, is not possible because of extensive metastatic disease, and survival rates have not improved over 30 years (Modlin et al. 2003, 2007). The NE phenotype is used for diagnosis, and it contributes to tumor-related morbidity and mortality. For example, the NE marker chromogranin A (CHGA) is used for NET diagnosis. Serotonin (5-HT) and other mediators stimulate NET growth and cause debilitating symptoms, such as diarrhea, flushing, wheezing, and right-sided valvular heart disease (i.e. carcinoid syndrome; Ishizuka et al. 1992, von Wichert et al. 2000). Current therapy has limited efficacy in shrinking tumors and is ineffective in palliating symptoms in the long term (Nakakura et al. 2007). Earlier diagnosis and
more effective therapies are needed, both of which require a better understanding of NET biology.

Although the origin of SI-NETs is not known, they are believed to arise from intestinal stem cells or endocrine cells. In the SI epithelium, multipotent stem cells generate endocrine cells, enterocytes, goblet cells, and Paneth cells (Schonhoff et al. 2004a). The transcription factor Math1 is required for the development of the SI secretory lineage, including endocrine, goblet, and Paneth cells (Yang et al. 2001). Another transcription factor, neurogenin3, initiates NE differentiation in immature cells (Jensen et al. 2000, Jenny et al. 2002, Lee et al. 2002, Schonhoff et al. 2004b). Additional transcription factors, such as Nkx2.2, Gfi1, Pax4, Pax6, NeuroD1, Pdx1, and Insm1, control the subsequent differentiation of endocrine cell subtypes (Schonhoff et al. 2004a, Shroyer et al. 2005, Gierl et al. 2006, Desai et al. 2008, Wang et al. 2009). Other transcription factors are also likely involved.

Many of the same transcription factors and signaling events that are essential for neuronal differentiation are also required for NE differentiation in normal and neoplastic gut. In the central nervous system (CNS), Nkx2.2, Ascl1, and Fev participate in a transcription factor pathway necessary to generate 5-HT neurons (Cheng et al. 2003, Pattyn et al. 2004). Recently, we and others showed that Nkx2.2 also functions in normal SI to control NE differentiation, regulating the production of numerous hormones, including 5-HT (Desai et al. 2008, Wang et al. 2009). In addition, we found that Nkx2.2 is expressed in most NETs of the GI tract, including SI-NETs (Wang et al. 2009). We also reported that Ascl1 is expressed in human GI-NETs and that Notch signaling inhibits GI-NET hormone production and growth, via a conserved mechanism present during normal development, wherein Notch activation inhibits the differentiation of gut endocrine cells by inhibiting the expression of pro-endocrine transcription factors (Nakakura et al. 2005).

Whether Fev functions in NE differentiation of normal or neoplastic SI is not known. FEV, also known as Pet-1 (PC12 ETS factor), is a member of the ETS oncogene family of transcription factors (Fyodorov et al. 1998). A chromosomal translocation encoding EWS/FEV or FUS/FEV fusion protein may mediate Ewing’s sarcoma development (Peter et al. 1997, Ng et al. 2007), and aberrant FEV expression has been described in malignant pancreatic NETs (Duerr et al. 2008). Fev is necessary for 5-HT neuron development, functioning downstream of Nkx2.2 and Ascl1 (Cheng et al. 2003, Pattyn et al. 2004), and cells that produce 5-HT are the most abundant SI endocrine cell type. In this study, we evaluated the role of FEV in the differentiation of 5-HT-producing cells in normal and neoplastic SI.

Materials and methods

Animals and human tissues

Fev, ePet-Cre, and Nkx2.2 transgenic mice were generated, maintained, and genotyped according to the regulations of the IACUC at the University of California San Francisco (UCSF) as described previously (Sussel et al. 1998, Hendricks et al. 2003, Scott et al. 2005). Human tissue samples were obtained from resection specimens after approval by the UCSF Committee on Human Research, which is the institutional IRB (IRB number: H6172-26943-05A).

Histology and immunohistochemistry

Tissues were fixed in Z-fix (Anatech, Battle Creek, MI, USA) and processed for paraffin or frozen sections as described (Scott et al. 2005, Wang et al. 2009). The following primary antibodies were used: rabbit anti-gastrin/CCK, which reacts with gastrin and CCK because they share a common carboxy-terminal tetrapeptide sequence necessary for bioactivity (Novocastra, Newcastle, UK), 1:200; goat anti-ghrelin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 1:200; mouse monoclonal anti-5-HT (Dako, Carpinteria, CA, USA), 1:4000; rabbit anti-5-HT (Immunostar), 1:1000; mouse monoclonal anti-CHGA (Immunostar, Hudson, MA, USA), 1:100; rabbit anti-5-HT (Immunostar), 1:4000; mouse monoclonal anti-5-HT (Dako, Carpinteria, CA, USA), 1:25; goat anti-β-galactosidase (β-gal; Biogenesis, Sandown, NH, USA), 1:2500. Secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) were FITC-conjugated goat anti-mouse and anti-rabbit, 1:200; FITC-conjugated donkey anti-goat, goat anti-rabbit, 1:200; Cy3-conjugated donkey anti-goat, goat antimouse, and goat anti-rabbit, 1:400. Slides were imaged on an Axiostar 2 microscope (Zeiss, Thornwood, NY, USA) or on an LSM510 META confocal microscope (Zeiss).

Cell quantification and data analysis

Multiple sections from the SI (duodenum) from at least three Fev (+/+) and Fev (−/−) mice were analyzed for each experiment. The number of cells per unit length of intestine was calculated for at least three different mice for each genotype, and a minimum of 15 mm of intestinal length was analyzed per animal. Results are expressed as mean ± S.E.M. Mean changes were compared using the Mann–Whitney U test. A value of P < 0.05 was considered to be statistically significant.
RNA analysis

Total RNA was isolated using the RNeasy Mini Kit (Qiagen) from the indicated tissues. First-strand cDNA was prepared from 1 μg of total RNA using the SuperScript III First-Strand cDNA Synthesis System (Invitrogen) and a combination of random hexamer and oligo dT primers. For TaqMan real-time PCR amplification, 30 ng of cDNA template were used. Quantity of cDNA template was measured using a spectrophotometer. All primer/probe sets were validated with a standard curve using serial cDNA dilutions. All assays were performed with ABI assay-on-demand and ABI TaqMan Universal PCR Master Mix. Quantification was done using an Opticon2 thermocycler (MJ Research, Waltham, MA, USA) following the manufacturer’s instructions. Results were normalized relative to the level of mouse GUSb mRNA, which was used as an internal control for cDNA quantity and quality. For RT-PCR analysis the following primers were used: gastrin, 5'-GTGTTGTTGCGATGCTCTTTAG-3' and 5'-GCGACCAAGTCTCATTCCATCCCG-3'; Cck, 5'-ACAACGACGTTCCGAAG-3' and 5'-CGATGGGTTATTCGTAGCTCTC-3'; secretin, 5'-GACGTTCCAGCGAGCTCAG-3' and 5'-CACTCTGAATGGCAGACA-3'; somatostatin, 5'-TCTCTCTGCTGGCAGACTCT-3' and 5'-GCCAAGAGGTCTTAGCC-3'; glucagon, 5'-ATCATTCGCTTGGACAGCTC-3' and 5'-GGTGTGTGGCCTAGTC-3'; FEV, 5'-GGTGTGTGCATGCTAGTC-3' and 5'-GACGTTCACCAGCGAGCTCAG-3'; ghrelin, 5'-CTCTGAATGGTCGACAGCA-3'; CCKα, 5'-TTCTCCATGGTGGTGAAGACA-3'; and Gapdh, 5'-CTCTTACATGGTGAGTTCG-3' and 5'-GCCAAGAAAGCTA-3'.

Results

**FEV is expressed in human SI-NETs that produce 5-HT**

To determine whether FEV is expressed in human SI-NETs, we identified 12 patients with well-differentiated SI-NETs for whom tissue was available. All patients had SI-NETs located in the ileum and lymph node metastases, and most (10/12) had liver metastases (Table 1). Every patient exhibited increased tumor 5-HT elaboration, which was evidenced by elevated urinary 24 h 5-hydroxyindoleacetic acid (5-HIAA) levels (12 of 12 patients; median = 45.6, range 7.9–520.6, normal < 6.0 mg/24 h) and/or the presence of the carcinoid syndrome (9 of 12 patients; Table 1). The following three findings are characteristic of SI-NETs: 1) an ileal primary tumor, 2) excessive 5-HT elaboration, and 3) frequent lymph node and liver metastases. None of the patients had multiple endocrine neoplasia (MEN) I syndrome.

FEV expression has been detected by northern blot analysis in human adult SI (Peter et al. 1997), but whether FEV is expressed in human SI-NETs is not known. Using qRT-PCR, we analyzed FEV expression in matched normal and tumor samples from the

Table 1 Characteristics of patients with well-differentiated neuroendocrine tumors of the small intestine

<table>
<thead>
<tr>
<th>Primary site</th>
<th>Lymph node metastasis</th>
<th>Liver metastasis</th>
<th>Serum CHGA (ng/ml)</th>
<th>Urine 24 h 5-HIAA (mg/24 h)</th>
<th>Carcinoid syndrome</th>
<th>MEN I syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ileum</td>
<td>Present</td>
<td>Present</td>
<td>320.9</td>
<td>63.9</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>ileum</td>
<td>Present</td>
<td>Present</td>
<td>758.5</td>
<td>520.6</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>ileum</td>
<td>Present</td>
<td>Present</td>
<td>195.0</td>
<td>7.9</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>ileum</td>
<td>Present</td>
<td>None</td>
<td>24.1</td>
<td>7.9</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>ileum</td>
<td>Present</td>
<td>Present</td>
<td>130.0</td>
<td>108.5</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>ileum</td>
<td>Present</td>
<td>ND</td>
<td>16.5</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>7</td>
<td>ileum</td>
<td>Present</td>
<td>Present</td>
<td>310.0</td>
<td>14</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>ileum</td>
<td>Present</td>
<td>None</td>
<td>133.2</td>
<td>27.2</td>
<td>No</td>
</tr>
<tr>
<td>9</td>
<td>ileum</td>
<td>Present</td>
<td>Present</td>
<td>51.8</td>
<td>14.2</td>
<td>Yes</td>
</tr>
<tr>
<td>10</td>
<td>ileum</td>
<td>Present</td>
<td>Present</td>
<td>ND</td>
<td>86.6</td>
<td>Yes</td>
</tr>
<tr>
<td>11</td>
<td>ileum</td>
<td>Present</td>
<td>Present</td>
<td>1675.8</td>
<td>176.6</td>
<td>Yes</td>
</tr>
<tr>
<td>12</td>
<td>ileum</td>
<td>Present</td>
<td>Present</td>
<td>122.0</td>
<td>92</td>
<td>Yes</td>
</tr>
</tbody>
</table>

CHGA, chromogranin A; 5-HIAA, 5-hydroxyindoleacetic acid; ND, not done; MEN, multiple endocrine neoplasia. Serum CHGA: normal < 36.4 ng/ml; Urine 24 h 5-HIAA: normal < 6.0 mg/24 h.
12 patients described above (Table 1). Compared with those in the matched normal ileum, FEV expression levels were significantly elevated in SI-NE primary tumors (20-fold, \(P < 0.0001\)), NET lymph node metastases (35-fold, \(P = 0.004\)), and NET liver metastases (22-fold, \(P < 0.0001\); Fig. 1). In contrast, FEV expression levels in normal human colon and in colon cancer liver metastases were very low (Fig. 1). We did not observe any correlation between FEV expression level and tumor burden, as reflected by serum CHGA level, urine 24-h 5-HIAA level, or liver involvement (data not shown). These findings indicate that elevated FEV expression is restricted to human SI-NETs that produce 5-HT, which may reflect utilization of a conserved pathway of NE differentiation in normal and neoplastic SI.

Overall, FEV expression was elevated in 96.5% (26/27) of human SI-NET samples when compared with the matched normal ileum. Specifically, FEV expression was increased in SI-NE primary tumors (11/11), NET lymph node metastases (6/7), and NET liver metastases (9/9). However, FEV expression levels in NET lymph node metastases (\(P = 0.72\)) and NET liver metastases (\(P = 0.76\)) were not significantly different from those in SI-NE primary tumors (Fig. 1). FEV expression levels in NET lymph node metastases were not significantly different from those in NET liver metastases (\(P = 0.92\); Fig. 1). Because FEV expression is detected in most human SI-NETs (i.e., in primary tumors as well as in their lymph node and liver metastases), but not in colon cancer liver metastases, we conclude that FEV is a novel SI-NET marker.

**FEV is expressed in 5-HT cells of normal mouse SI**

Low levels of Fev expression have been detected in rat SI by RNase protection analysis, but the identity of the cell type expressing Fev is not known (Fyodorov et al. 1998). No antibodies raised against Fev have been validated for immunohistochemical or immunofluorescence (IF) analysis. We and others found that the homeodomain transcription factor Nkx2.2 is required for the development of 5-HT-producing cells in mouse SI (Desai et al. 2008, Wang et al. 2009). In the CNS, Fev is necessary for 5-HT neuron development, functioning downstream of Nkx2.2 (Cheng et al. 2003), but whether Fev functions in enteroendocrine differentiation downstream of Nkx2.2 is not known. In Nkx2.2 mutant SI, cells that produce 5-HT are absent (Desai et al. 2008, Wang et al. 2009). Consistent with this, we found that mRNA levels of tryptophan hydroxylase 1 (Tph1), which catalyzes the rate-limiting step in 5-HT biosynthesis in the SI, were absent in Nkx2.2 (−/−) SI (Fig. 2A), which confirms our prior findings (Wang et al. 2009). Next, we analyzed Fev expression in wild-type and Nkx2.2 (−/−) SI. We readily detected Fev expression in wild-type mouse SI (Fig. 2A). However, Fev mRNA levels were depleted in Nkx2.2 mutant SI, which lacks 5-HT cells (Fig. 1). These results suggest that Fev expression is dependent on Nkx2.2, and that Fev may be expressed in 5-HT cells in normal mouse SI.

To determine whether Fev-expressing cells give rise to 5-HT cells in the SI, we used recombination-based cell lineage tracing. The ePet-Cre transgenic mouse line uses the Fev enhancer region to reliably direct the expression of Cre recombinase to 5-HT neurons in the CNS, faithfully recapitulating the spatiotemporal pattern of Fev expression in the CNS (Scott et al. 2005). Whether ePet-Cre mice drive expression of Cre recombinase in 5-HT-producing enteroendocrine cells in the SI is not known. We crossed ePet-Cre mice with the Rosa26 reporter line to generate R26R<sup>Cre</sup> mice. Cells and their descendants that utilize the Fev enhancer, even transiently, are permanently marked by β-gal. By IF analysis, we detected β-gal expression

![Figure 1](https://www.endocrinology-journals.org/fig1.png)

**Figure 1** Fev is expressed in human well-differentiated NETs of the small intestine. Real-time TaqMan RT-PCR analysis shows Fev expression in matched ileum NET primary tumors (\(n = 11\)), lymph node metastasis (\(n = 7\)), and liver metastasis (\(n = 9\)). For comparison, Fev expression levels in normal colon (\(n = 2\)) and colon cancer liver metastasis (\(n = 5\)) are shown. Values are normalized to normal ileum samples (\(n = 12\)). Bar denotes median.
in rare cells located in the epithelium of R26RePetCre mouse SI, showing Fev is indeed expressed in the SI epithelium (Fig. 2B and C). Expression of β-gal was present throughout the crypt-villus axis of the SI in a pattern reminiscent of endocrine cells.

Next, to determine whether 5-HT-producing cells of the SI arise from Fev-positive cells, we performed double IF analysis. Serotonin is the most predominant hormone in the SI, and we detected co-localization of 5-HT-positive and β-gal-positive cells along the crypt-villus axis of the SI (Fig. 2G and K). All 5-HT-producing cells in the SI also expressed β-gal (277/277), suggesting that, as in the CNS, 5-HT-producing cells in the SI arise from an Fev-expressing cell. These results suggest a conserved role for Fev in the differentiation of 5-HT-producing cells in the CNS and SI. Moreover, we concluded that Fev expression identifies 5-HT-producing cells in normal mouse SI.

Fev (−/−) mice do not exhibit defects in SI endocrine cell number or hormone expression

To elucidate the role of FEV in intestinal endocrine cell development, we analyzed the proximal SI (duodenum) in Fev (−/−) mice at E18.5. Routine H&E staining showed no abnormalities in the appearance of Fev (−/−) SI (data not shown). As an initial screen for an intestinal endocrine phenotype, we assayed for the expression of the general NE marker CHGA by qRT-PCR and IF analysis. We observed no difference in Chga mRNA level (Fig. 3A; \( P = 1.0 \)) or the number of CHGA-positive cells (Fig. 4A–C; \( P = 0.14 \)) in the SI of Fev (−/−) mice compared with the wild type.

Serotonin-producing cells are the most abundant intestinal endocrine cell type. When we assayed for 5-HT expression by IF analysis, we did not detect a difference in 5-HT cell number in the SI of Fev (−/−) mice compared with the wild type (Fig. 4D–F; \( P = 0.86 \)). Consistent with this, mRNA levels of Tph1, which catalyzes the rate-limiting step in 5-HT

Figure 2 Fev is expressed in serotonin-producing cells of the mouse small intestine. Expression of indicated genes in the duodenum of Nkx2.2 (+/+)(\( n = 3 \)) and Nkx2.2 (−/−)(\( n = 3 \)) mouse embryos at E18.5 by real-time TaqMan RT-PCR (A). Compared with Nkx2.2 (+/+), intestine, near absence of Fev and Tph1 expression is observed in Nkx2.2 (−/−) intestine (A). (B–K) Immunofluorescence experiments of duodenal sections obtained from adult R26RePetCre mice with the antibodies indicated. Immunofluorescent staining for β-gal shows ePetCre-induced LacZ expression in rare cells in the intestinal epithelium (B and C). (D–K) Co-expression of β-gal and 5-HT in cells of the intestinal epithelium. (D and H) DAPI identifies nuclei. Immunofluorescent staining for 5-HT (E and I, green) and β-gal (F and J, red) with merged image (G and K) showing yellow double-stained cells.
biosynthesis in the gut, were unchanged in Fev (−/−) SI as assayed by qRT-PCR (Fig. 3A; $P = 0.72$). We also examined the expression of Cck, gastrin, glucagon, secretin, somatostatin, and tachykinin precursor 1 (Tac1), which encodes for substance P, by RT-PCR and did not detect any differences in Fev (−/−) SI compared with the wild type (Fig. 3B). The glucagon gene encodes for preproglucagon, which undergoes post-translational processing to produce glucagon, GLP-1, and GLP-2.

In Nkx2.2 (−/−) mouse SI, an increase in ghrelin-producing cells is associated with depletion of most endocrine cell types (Desai et al. 2008, Wang et al. 2009). Since we found that Fev expression is diminished in Nkx2.2 (−/−) SI (Fig. 2A), we next investigated ghrelin expression in Fev (−/−) SI. As shown by qRT-PCR assay, ghrelin expression in Fev mutant SI increased only 1.7-fold ($P = 0.08$; Fig. 3A). IF analysis showed no difference in the number of ghrelin cells in Fev (−/−) SI ($P = 0.66$; Fig. 4G–I). Although Fev is critical for the development of 5-HT neurons in the CNS, our analysis did not reveal any difference in the number of cells that produce 5-HT or other hormones in Fev (−/−) SI.

**Discussion**

Informed by observations from developmental neurobiology of the important role of the ETS oncogene family transcription factor Fev in the differentiation of 5-HT-producing neurons, we have shown here that FEV is expressed in SI-NETs – in the primary tumor as well as in lymph node and liver metastases. Every patient who underwent resection of the SI-NET had evidence of increased 5-HT elaboration. We have also shown that Fev-expressing cells give rise to 5-HT-producing cells in normal mouse SI. Our findings suggest that FEV expression identifies 5-HT-producing cells in normal and neoplastic SI.

Recently, we and others showed that the homeodomain transcription factor Nkx2.2 functions in normal SI to control NE differentiation (Desai et al. 2008, Wang et al. 2009), and that it is expressed in SI-NETs (Wang et al. 2009). Given that Nkx2.2 and Fev act together in NE differentiation in the CNS (Cheng et al. 2003), we hypothesized that Fev might also play an important role, similar to Nkx2.2, in SI NE differentiation. Although Fev expression is restricted to 5-HT neurons in the CNS and is critical for their development (Hendricks et al. 2003), we detected no difference in the number of cells producing 5-HT or any other hormone in the SI of Fev (−/−) mice. Reasons for the differences in NE phenotype in the CNS versus SI in Fev (−/−) mice despite the expression of Fev in 5-HT cells in both tissues may reflect differences in genetic redundancy between the CNS and SI. For example, transcription factors other than Fev might be required for the development of 5-HT-producing cells in the SI. Interestingly, we detected increases in neurogenin3 and Pax4 mRNA levels in Fev (−/−) SI, which raises the possibility that increases in their expression may compensate for Fev loss in the SI (data not shown).

Because Fev expression is restricted to 5-HT neurons in the CNS (Scott et al. 2005), our analysis of Fev expression focused on normal and neoplastic SI, where 5-HT is the predominant hormone that is produced. However, Fev is expressed in malignant pancreatic NETs, which are believed to only rarely produce 5-HT (Duerr et al. 2008). Therefore, Fev could be expressed in NETs that produce hormones other than 5-HT. It is also possible that Fev is expressed in NETs derived from sites other than the SI and pancreas. Importantly, we found here that Fev expression is very low in colorectal liver metastases. Thus, our data show that Fev expression is not a general feature of adenocarcinomas. We also found that Fev-expressing cells give rise to gastrin/CKK cells
in normal mouse SI (Supplementary Figure 1, see section on supplementary data given at the end of this article). Therefore, outside the CNS, Fev expression does not appear to be limited to 5-HT cells.

Fev, Nkx2.2, and Ascl1 share much in common. All three are pro-endocrine transcription factors essential for the development of 5-HT neurons in the mouse CNS (Pattyn et al. 2004). These transcription factors are also expressed in human SI-NETs, which characteristically elaborate 5-HT (Nakakura et al. 2005, Wang et al. 2009). Elaboration of 5-HT by SI-NETs stimulates tumor growth and causes the debilitating symptoms present in the carcinoid syndrome (Ishizuka et al. 1992, von Wichert et al. 2000). Thus, further study of FEV, Nkx2.2, and Ascl1 functions in SI-NETs has the potential to provide insight into the determinants of 5-HT production, which may result in a better understanding of NE tumorigenesis.

In addition to their link with the 5-HT phenotype in normal and neoplastic tissues, FEV, Nkx2.2, and Ascl1 have all been associated with tumorigenesis in diverse cancers. Ascl1 promotes tumor progression in lung cancers with NE features (Llinoila et al. 2000, Osada et al. 2005). Nkx2.2 promotes tumorigenesis in Ewing’s sarcoma (Smith et al. 2006). FEV may also promote tumorigenesis in Ewing’s sarcoma (Peter et al. 1997, Ng et al. 2007). None of the patients included in our study had MEN I syndrome, so we are unable to speculate on any potential interaction between menin and FEV in SI-NETs. It is tempting to speculate that FEV, Nkx2.2, and Ascl1 might cooperate to promote tumor progression in SI-NETs. Pro-endocrine transcription factors may have dual functions in SI-NETs. They may regulate NE differentiation and promote tumor progression. Therefore, investigations into the function of pro-endocrine transcription factors in appropriate NET models and cell lines may provide important insight into NET biology.

NETs comprise a heterogeneous group of neoplasms (Nakakura et al. 2007). Currently, NETs are diagnosed on the basis of morphology, expression of general NE markers (e.g. CHGA), and production of hormones; however, based on these findings alone, the particular NET type cannot be elucidated often. We have identified three developmental transcription factors – Fev, Nkx2.2, and Ascl1 – expressed in SI-NETs (Nakakura et al. 2005, Wang et al. 2009). Although the expression pattern for each of these individual genes is known, the combinations of their expression have not been characterized in NETs. Further work may permit us to identify NETs not on the basis of morphology but on the basis of transcriptional
programs. Such information may suggest the tumor location in patients with metastatic disease and unknown primary tumors. Moreover, such information may help provide insight into the lineage of NETs, which may result in the identification of NET stem cells or different classes of progenitors.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1677/ERC-09-0243.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by the James Ewing Oncology Fellowship Award (to E K Nakakura), American College of Surgeons Faculty Research Fellowship (to E K Nakakura), University of California Cancer Research Coordinating Committee (to E K Nakakura), UCSF Research Evaluation and Allocation Committee (REAC) Grant (to E K Nakakura), Novartis Oncology provided through the Cancer and Leukemia Group B Foundation (to E K Nakakura), the V Foundation for Cancer Research (to E K Bergsland, E K Nakakura), the Larry L Hillblom Foundation grant 2007/1B (to M S German), and the National Institutes of Health grants R01 DK021344 and P30 DK63720 (to M S German).

Acknowledgements
We thank the UCSF Mouse Pathology Core for help with tissue processing and Pamela Derish for editorial assistance.

References


Modlin IM, Moss SF, Chung DC, Jensen RT & Snyderwine E 2008 Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. Journal of the National Cancer Institute 100 1282–1289.


Sussel L, Kalamara J, Hartigan-O’Connor DJ, Meneses JJ, Pedersen RA, Rubenstein JL & German MS 1998 Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. *Development* **125** 2213–2221.

